Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

NCT07707778 on ClinicalTrials.gov · last registry update 2026-07-20

60 participants. Due to report December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Second generation epigenetic aging clock. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for diabetes and mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ENROLLING_BY_INVITATION
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: National Taiwan University Clinical Trial Center
Sponsor type: Other
Enrollment: 60
Started: 2026-06-25
Primary completion: 2027-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Second generation epigenetic aging clock

Conditions studied

Human Immunodeficiency Virus (HIV) · Metabolic Dysfunction Associated Steatotic Liver Disease · Dyslipidaemia · Diabetes Mellitus · Obesity & Overweight · Metabolic Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.